To elucidate the relationship between del(5q) and the clinical and histological features of small cell neuroendocrine lung carcinoma, 33 tissue samples from patients with this tumor were evaluated. By using fluorescence in situ hybridization, del(5q) was identified in almost 50% of cases (15/33, 45%). Clinically, patients with tumors showing del(5q) were older (mean age = 71 years) with a correspondingly greater pack-year smoking history (mean = 61) than patients with tumors (mean age = 59 years, mean pack-years = 44) without del(5q). Histologically, tumors with del(5q) had a greater frequency of spindle cell morphology (11/14 [79%] vs 6/16 [38%], P < .025) than those without del(5q). This is the first study to find an association between del(5q) and tumor histology in small cell neuroendocrine lung carcinoma.
Travis WD, Brambilla E., Muller-Hermelink HK, Harris CCWorld Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus, and Heart. Lyon , France: IARC Press;2004:344.
2.
Fong KM, Sekido Y., Minna JDMolecular pathogenesis of lung cancer. J Thorac Cardiovasc Surg. 1999;118: 1136-1152.
3.
Girard L., Zochbauer-Muller S., Virmani AK, Gazdar AF, Minna JDGenome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res. 2000;60:4894-4906.
4.
Miura I., Graziano SL, Cheng JQ, Doyle LA, Testa JRChromosome alterations in human small cell lung cancer: frequent involvement of 5q. Cancer Res.1992;52: 1322-1328.
5.
Hosoe S., Ueno K., Shigedo Y., et al. A frequent deletion of chromosome 5q21 in advanced small cell and non-small cell carcinoma of the lung. Cancer Res. 1994; 54:1787-1790.
6.
Schwendel A. , Langreck H., Reichel M., et al. Primary small-cell lung carcinomas and their metastases are characterized by a recurrent pattern of genetic alterations . Int J Cancer. 1997;74:86-93.
7.
Onuki N., Wistuba II, Travis WD, et al. Genetic changes in the spectrum of neuroendocrine lung tumors . Cancer. 1999;85:600-607.
8.
Whang-Peng J. , Kao-Shan CS, Lee EC, et al. Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23). Science . 1982;215:181-182.
9.
Walch AK, Zitzelsberger HF, Aubele MM, et al. Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization. Am J Pathol. 1998;153:1089-1098.
10.
Ullmann R., Petzmann S., Sharma A., Cagle PT, Popper HHChromosomal aberrations in a series of large-cell neuroendocrine carcinomas: unexpected divergence from small-cell carcinoma of the lung. Hum Pathol. 2001;32:1059-1063.
Ashman JN, Brigham J., Cowen ME, et al. Chromosomal alterations in small cell lung cancer revealed by multicolour fluorescence in situ hybridization. Int J Cancer . 2002;102:230-236.
13.
Tamura K., Miwa W., Maruyama T., Sekiya T., Murakami, Y.Homozygous deletion on the chromosomal region 5q12.3 in human lines of small-cell lung cancers. J Hum Genet.2002;47:348-354.
14.
Mendes-da-Silva P., Moreira A., Duro-da-Costa J., Matias D., Monteiro C.Frequent loss of heterozygosity on chromosome 5 in non-small cell lung carcinoma. Mol Pathol. 2000;53:184-187.
15.
Goguel AF, Fouquet F., Duverger A., et al. Evolution of chromosomal alterations and biologic features in two small cell lung carcinoma cell lines established from one patient during the course of the disease. Cancer Genet Cytogenet. 1995;80:47-54.
16.
Smith JS, Perry A., Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. 2000;18:636-645.
17.
Morel P., Hebbar M., Lai JL, et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia. 1993 ;7:1315-1323.
18.
Grimwade D. , Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322-2333.
19.
Dohner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia . N Engl J Med. 2000;343:1910-1916.
